[go: up one dir, main page]

MX2018003333A - Formulaciones de liberacion controlada. - Google Patents

Formulaciones de liberacion controlada.

Info

Publication number
MX2018003333A
MX2018003333A MX2018003333A MX2018003333A MX2018003333A MX 2018003333 A MX2018003333 A MX 2018003333A MX 2018003333 A MX2018003333 A MX 2018003333A MX 2018003333 A MX2018003333 A MX 2018003333A MX 2018003333 A MX2018003333 A MX 2018003333A
Authority
MX
Mexico
Prior art keywords
vomiting
nausea
compositions
formulation
devices
Prior art date
Application number
MX2018003333A
Other languages
English (en)
Inventor
Tiberg Fredrik
Johnsson Markus
Barauskas Justas
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2018003333A publication Critical patent/MX2018003333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención se refiere a una preformulación inyectable que comprende una mezcla de baja viscosidad de: a) al menos un lípido de diacilo neutro y/o al menos un tocoferol; b) al menos un fosfolípido; c) al menos un solvente orgánico que contiene oxígeno; d) al menos un antagonista de SHT3; en donde la preformulación forma, o es capaz de formar, al menos una estructura de fase cristalina líquida tras el contacto con un fluido acuoso. Tales composiciones pueden comprender, además, solventes polares y/o agentes activos adicionales, tales como agonistas y/o antagonistas de opioides. Se proporcionan métodos de tratamiento, en particular para el tratamiento de náuseas y vómitos. tales como náuseas y vómitos posoperatorios y/o náuseas y vómitos inducidos por la terapia, así como los correspondientes usos de las composiciones. También se proporcionan dispositivos de administración que comprenden las formulaciones y kits que comprenden los dispositivos.
MX2018003333A 2015-09-18 2016-09-16 Formulaciones de liberacion controlada. MX2018003333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1516554.1A GB201516554D0 (en) 2015-09-18 2015-09-18 Controlled-release formulations
PCT/EP2016/072059 WO2017046384A1 (en) 2015-09-18 2016-09-16 Controlled-release formulations

Publications (1)

Publication Number Publication Date
MX2018003333A true MX2018003333A (es) 2018-08-15

Family

ID=54544453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003333A MX2018003333A (es) 2015-09-18 2016-09-16 Formulaciones de liberacion controlada.

Country Status (13)

Country Link
US (1) US20180256496A1 (es)
EP (1) EP3349800A1 (es)
JP (1) JP2018528964A (es)
KR (1) KR20180085716A (es)
CN (1) CN108601843A (es)
AR (1) AR106049A1 (es)
AU (1) AU2016323732A1 (es)
CA (1) CA2998966A1 (es)
GB (1) GB201516554D0 (es)
HK (1) HK1258718A1 (es)
MX (1) MX2018003333A (es)
TW (1) TW201717946A (es)
WO (1) WO2017046384A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326613A1 (en) 2012-07-26 2018-05-30 Camurus AB Opioid formulations
MX387722B (es) 2012-07-26 2025-03-18 Camurus Ab Formulaciones de opioides.
SG11201703632WA (en) 2014-11-07 2017-06-29 Indivior Uk Ltd Buprenorphine dosing regimens
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3863712A4 (en) * 2018-10-11 2022-07-20 Indivior UK Limited BUPRENORPHINE USED TO TREAT RESPIRATORY DEPRESSION
WO2021043771A1 (en) 2019-09-02 2021-03-11 Camurus Ab Formulations and treatment methods
WO2021064580A1 (en) * 2019-10-01 2021-04-08 Shilpa Medicare Limited Controlled release injectable ondansetron formulations
GB2618507B (en) * 2021-02-18 2025-02-19 Navin Saxena Research And Tech Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
CN113081954A (zh) * 2021-05-25 2021-07-09 南昌大学第二附属医院 一种凝胶载药贴剂药物输送系统
CN115702894A (zh) * 2021-08-11 2023-02-17 朱信红 一种用于止吐的缓释组合物及其制备方法
CN119280165A (zh) * 2024-10-16 2025-01-10 浙江大学 基于脂质液晶技术的长效镇痛组合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
EP1845942B1 (en) * 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
WO2010065930A1 (en) * 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂
EP3326613A1 (en) * 2012-07-26 2018-05-30 Camurus AB Opioid formulations
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US20140323517A1 (en) * 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system

Also Published As

Publication number Publication date
HK1258718A1 (zh) 2019-11-15
GB201516554D0 (en) 2015-11-04
US20180256496A1 (en) 2018-09-13
AR106049A1 (es) 2017-12-06
AU2016323732A1 (en) 2018-04-12
CA2998966A1 (en) 2017-03-23
KR20180085716A (ko) 2018-07-27
WO2017046384A1 (en) 2017-03-23
CN108601843A (zh) 2018-09-28
EP3349800A1 (en) 2018-07-25
TW201717946A (zh) 2017-06-01
JP2018528964A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
MX2018003333A (es) Formulaciones de liberacion controlada.
MX361716B (es) Formulaciones peptidicas de liberacion controlada.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
CL2019002032A1 (es) Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018).
MX350929B (es) Formulaciones peptidicas robustas de liberación controlada.
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
CU20150090A7 (es) Derivados de benzotiofeno y composiciones de los mismos como degredantes selectivos de los receptores de estrógenos
AU2014338549A8 (en) Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
MX389333B (es) Formulacion de buprenorfina inyectable.
MX2016012668A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
EA201992679A1 (ru) N-замещенные индольные производные
EA201791166A1 (ru) Препараты с контролируемым высвобождением
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
EA201591904A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
CO2022008313A2 (es) Compuestos químicos
MX2017016939A (es) Novedosas antagonistas 5-ht2.
TN2014000483A1 (en) Somatostatin receptor agonist formulations
EA201390921A1 (ru) НОВЫЕ ПРОТИВОГРИБКОВЫЕ 5,6-ДИГИДРО-4H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНЫ И 6H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНЫ, ЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИМИ ПРОИЗВОДНЫМИ БЕНЗОЛА
MX2018015707A (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.
BR112015023750A2 (pt) composição agricolamente ativa concentrada; método de preparação da composição pronta para uso; composição pronta para uso; e método para o tratamento de uma planta
MA41158A (fr) Composition pharmaceutique comprenant un composé d'amide hétérocyclique aromatique contenat de l'azote bicyclique en tant que principe actif
EA201391630A1 (ru) Новые противогрибковые 5,6-дигидро-4h-пирроло[1,2-a][1,4]бензодиазепины и 6h-пирроло[1,2-a][1,4]бензодиазепины, замещенные гетероциклическими производными